FDA
-
-
-
-
-
-
-
Gilead (GILD) to Acquire Forty Seven (FTSV) for $4.9 Billion, $95.50/Share in Cash
-
-
-
-
-
-
-
Forty Seven (FTSV) Highlights Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab
-
-
-
-
-
-
-
Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
-
-
-
-
-
-
-
Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Forty Seven Inc. Appoints Leading Experts in Immuno-Oncology to its Scientific Advisory Board (SAB)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

